Considering TREM2 also has different roles in AD-related myeloid cell functions early and late in disease progression (31, 46), TREM2 is generally protective for microglial activation and tau pathology in the early stage, then changes their phenotype to accelerate neurodegeneration and inflammation in a later stage. This evidence concerns the gene MAPT and Alzheimer disease.